Perdoceo Education

PRDO · NASDAQ

$33.37−$0.38 (−1.13%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $33.75

PRDO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $44.88 (+34.5% upside)

Low: $44.44
Now: $33.37
High: $46.20

Upgrades and downgrades

The latest rating actions, newest first

PRDO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barrington Research	Apr 27, 2026	Maintains	Outperform	$42.00	63%
Barrington Research	Jan 5, 2026	Maintains	Outperform	$42.00	63%
Barrington Research	Nov 5, 2025	Maintains	Outperform	$42.00	63%
Barrington Research	Oct 21, 2025	Maintains	Outperform	$42.00	63%

The case for and against

Updated Jan 19, 2026

Bull case

Perdoceo Education Corp has demonstrated strong growth, with total student enrollment at American InterContinental University (AIUS) increasing by 7.1% to 10,600 students, which now constitutes 23% of the company's overall enrollment. The company's segment operating income rose by 7.9%, reaching $46.3 million with a margin of 39.2%, fueled by higher revenue across its segments and an improved operating performance. Additionally, the company reported a significant increase in free cash flow, which rose by 26.8% to $178.8 million in the first nine months of the fiscal year, reflecting robust financial health and operational efficiency.

Bear case

Perdoceo Education Corp has reported a decrease in segment operating income by 6.5% to $12.1 million, reflecting a decline in margin from 24.1% to 22.1%, primarily due to a non-recurring expense benefit recognized in the previous year. Additionally, enrollment at the American InterContinental University System saw a 2.9% decline, and revenues from the segment, which accounts for 26.8% of total sales, fell by 1.2% to $56.7 million, exacerbated by a reduced number of enrollment days linked to the academic calendar. Although management's guidance for operating income in Q3/25 exceeds prior estimates, the underlying declines in revenue and enrollment across key segments underscore a challenging operational landscape that contributes to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.